{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:00:22Z","timestamp":1781078422453,"version":"3.54.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106882","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T07:49:54Z","timestamp":1764056994000},"page":"106882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness of rituximab in the treatment of multiple sclerosis: A multicenter, retrospective, observational study in morocco"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-2422","authenticated-orcid":false,"given":"Jawad","family":"Oumerzouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Hafidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abdellaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Chraa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bourazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106882_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101980","article-title":"Rituximab in the treatment of multiple sclerosis in the hospital district of Southwest Finland","volume":"40","author":"Airas","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2025.106882_bib0002","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1007\/s00415-018-8899-3","article-title":"Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study","volume":"265","author":"Alcal\u00e1","year":"2018","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0003","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00415-019-09195-2","article-title":"Treatment with Alemtuzumab or Rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe","volume":"266","author":"Alcala","year":"2019","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106882_bib0004","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/WNF.0000000000000268","article-title":"Safety and efficacy of Rituximab: experience of a single multiple sclerosis center","volume":"41","author":"Alldredge","year":"2018","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.msard.2025.106882_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14712598.2019.1611778","article-title":"CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date","volume":"19","author":"Ancau","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.msard.2025.106882_bib0006","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s40263-021-00843-8","article-title":"Clinical perspectives on the molecular and pharmacological attributes of AntiCD20 therapies for Multiple sclerosis","volume":"35","author":"Bar-Or","year":"2021","journal-title":"CNS. Drugs"},{"issue":"10","key":"10.1016\/j.msard.2025.106882_bib0007","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1007\/s10072-020-04434-1","article-title":"Experience with rituximab therapy in a real-life sample of multiple sclerosis patients","volume":"41","author":"Bellinvi","year":"2020","journal-title":"Neurol. Sci."},{"issue":"8","key":"10.1016\/j.msard.2025.106882_bib0008","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/ene.13936","article-title":"Natalizumab, Rituximab and Fingolimod as escalation therapy in multiple sclerosis","volume":"26","author":"Boremalm","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106882_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106882_bib0010","article-title":"Adverse event profile differences between Rituximab and Ocrelizumab: findings from the FDA Adverse event Reporting Database","author":"Caldito","year":"2020","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106882_bib0011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis-from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106882_bib0012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106882_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102787","article-title":"Comparison of the efficacy and safety of Anti-CD20 B cells depleting drugs in multiple sclerosis","volume":"49","author":"Cotchett","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0014","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.msard.2025.106882_bib0015","article-title":"Comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with Ocrelizumab vs low dose of Rituximab in Multiple sclerosis","volume":"6","author":"Evertsson","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106882_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1060696","article-title":"Treatment of multiple sclerosis with rituximab: a Spanish multicenter experience","volume":"14","author":"Gasc\u00f3n-Gim\u00e9nez","year":"2023","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106882_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2020.102585","article-title":"Efficacy and safety of Rituximab in treating patients with multiple sclerosis (MS): a systematic review and meta-analysis","volume":"19","author":"Ghajarzadeh","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.msard.2025.106882_bib0018","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD","volume":"8","author":"Graf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0019","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of Rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMa Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106882_bib0020","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ane.13225","article-title":"Rituximab in multiple sclerosis at general hospital level","volume":"141","author":"Hellgren","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.msard.2025.106882_bib0021","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ane.13225","article-title":"Rituximab in multiple sclerosis at general hospital level","volume":"141","author":"Hellgren","year":"2020","journal-title":"Acta Neurol. Scand."},{"issue":"10","key":"10.1016\/j.msard.2025.106882_bib0022","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1177\/1352458521998937","article-title":"Rituximab for treatment of refractory multiple sclerosis relapses during pregnancy","volume":"27","author":"Hollen","year":"2021","journal-title":"Mult. Scler."},{"issue":"7","key":"10.1016\/j.msard.2025.106882_bib0023","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/WNL.0000000000006916","article-title":"Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis","volume":"92","author":"Honce","year":"2019","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.msard.2025.106882_bib0024","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.msard.2025.106882_bib0025","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","article-title":"Efficacy and safety of Rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"18","author":"Hu","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.msard.2025.106882_bib0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1352458519858604","article-title":".Rituximab treatment for multiple sclerosis","volume":"26","author":"Ineichen","year":"2020","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0027","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurotherapeutics."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0028","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"AntiCD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106882_bib0029","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3325\/cmj.2019.60.87","article-title":"Therapies for multiple sclerosis targeting B cells","volume":"60","author":"Milo","year":"2019","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.msard.2025.106882_bib0030","article-title":"Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen Pharmed) in Iranian multiple sclerosis patients: an observational study","volume":"36","author":"Moghadasi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14712598.2019.1568407","article-title":"B cell depletion in the treatment of multiple sclerosis","volume":"19","author":"Myhr","year":"2019","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.msard.2025.106882_bib0032","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","article-title":"Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis","volume":"76","author":"Naegelin","year":"2019","journal-title":"JAMa Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106882_bib0033","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaneurol.2018.4239","article-title":"Association of Rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis","volume":"76","author":"Naegelin","year":"2019","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106882_bib0034","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cellimm.2018.10.006","article-title":"The role of B cells in multiple sclerosis: current and future therapies","volume":"339","author":"Negron","year":"2019","journal-title":"Cell Immunol."},{"issue":"15\u201316","key":"10.1016\/j.msard.2025.106882_bib0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10354-022-00939-w","article-title":"An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis","volume":"172","author":"Ovchinnikov","year":"2022","journal-title":"Wien. Med. Wochenschr."},{"key":"10.1016\/j.msard.2025.106882_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.595547","article-title":"Anti-CD20 B cell treatment for relapsing multiple sclerosis","volume":"11","author":"Roach","year":"2021","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106882_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197415","article-title":"Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland","volume":"13","author":"Scotti","year":"2018","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.msard.2025.106882_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102492","article-title":"Immunological consequences of \u201cimmune reconstitution therapy\u201d in multiple sclerosis: a systematic review","volume":"19","author":"Sellner","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"5","key":"10.1016\/j.msard.2025.106882_bib0039","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/03007995.2020.1739009","article-title":"Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review","volume":"36","author":"Siddiqui","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.msard.2025.106882_bib0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-021-00677-1","article-title":"Early aggressive treatment approaches for multiple sclerosis","volume":"23","author":"Simpson","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106882_bib0041","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of Rituximab relative to IFN-beta or glatiramer acetate in RelapsingRemitting MS from the Swedish MS Registry","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106882_bib0042","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106882_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2020.577317","article-title":"Efficacy and safety of Rituximab in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"347","author":"Tian","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106882_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577317","article-title":"Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis","volume":"347","author":"Tian","year":"2020","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.msard.2025.106882_bib0045","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/acn3.51111","article-title":"Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2025.106882_bib0046","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1177\/1352458519872889","article-title":"Treatment of multiple sclerosis with rituximab: a multicentric Italian\u2013Swiss experience","volume":"26","author":"Zecca","year":"2020","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2025.106882_bib0047","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1007\/s13311-020-00950-2","article-title":"The pharmacogenetics of Rituximab: potential implications for anti-CD20 therapies in multiple sclerosis","volume":"17","author":"Zhong","year":"2020","journal-title":"Neurotherapeutics."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:28:46Z","timestamp":1781076526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"alternative-id":["S2211034825006145"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106882","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of rituximab in the treatment of multiple sclerosis: A multicenter, retrospective, observational study in morocco","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106882"}}